Results 81 to 90 of about 21,002 (228)
Pharmacoeconomics and its importance in psychiatry [Farmakoekonomi ve psikiyatrideki önemi]
, 2010 The budget for health is limited in Turkey and other developing countries. In order to use the sources as good as possible, for rational drug use, it is necessary to consider economomical outcomes besides efficacy and safety.
core +1 more source
PHARMACOECONOMICS AND COST EFFECTIVE THERAPY PLANNING
Pharmacoeconomics plays a vital role in modern healthcare by evaluating the cost, effectiveness, and overall value of pharmaceutical therapies to ensure optimal patient outcomes with efficient resource utilization.
Dr. Gunjan, Smita Acharya
core +2 more sources
Cost Effectiveness and Resource AllocationBackground Although advances in multi-line cancer treatment have improved patient survival outcomes, they have also introduced significant economic and resource-allocation challenges.
Hao Li +4 more
doaj +1 more source
Psychogeriatrics, Volume 26, Issue 6, November 2026.ABSTRACT Background Assessment scales to detect subtle declines in activities of daily living (ADL) among patients with mild cognitive impairment (MCI) are needed for early diagnosis and support. This study examined the psychometric properties of the Japanese version of the Alzheimer's Disease Cooperative Study‐Activities of Daily Living for Mild ...
Daiki Ishimaru +11 more
wiley +1 more source
Measuring value: pharmacoeconomics in theory and practice
, 2011 In ‘Measuring value with pharmacoeconomics’, the authors outline the evolution of cost-effectiveness analysis (CEA) through its use as part of HTA. They also explore the theoretical and practical issues that have arisen as the result of using CEA of ...
Sorenson, Corinna +2 more
core +3 more sources
Navigating Healthcare Economics Optimizing Therapeutic Efficacy and Cost with Pharmacoeconomics
Journal of Pharmacoeconomics and Pharmaceutical ManagementBackground: In today's healthcare landscape, escalating costs underscore the pressing need for pharmacoeconomic evaluations, particularly in low- and middle-income countries (LMICs) where medication expenses can dominate healthcare budgets ...
Rania Indu, Moumita Ray, Sudipto Mangal
doaj
Pharmacoeconomics of Bronchial Asthma
Folia Medica, 2019 Introduction: Pharmacoeconomics (PE) treats the problems of pharmacotherapy policy, drug marketing and reimbursement and clinical trials. It guides policy makers for effective health resources utilization and determines the profitability of the new drugs
Ivanova Zlatina I., Ivanov Yavor Y.
doaj +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3460-3465, October 2026.Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest +4 more
wiley +1 more source
PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
Кардиоваскулярная терапия и профилактика, 2015 Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj +1 more source
Health Economics, Volume 35, Issue 10, Page 1468-1481, October 2026.ABSTRACT Gender incongruence in trans and nonbinary (“trans”) populations is often associated with psychological distress and increased demand for mental healthcare. Gender‐affirming hormone therapy (GAHT) is a key component of care for many trans people, yet long‐term evidence around its cost implications remains limited despite increasing uptake and ...
Karinna Saxby +2 more
wiley +1 more source